Why 'promising research' is not the same as lawful commercial availability

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: Patients, journalists, investors, and anyone who has read about a positive clinical trial and wants to understand why the drug is not yet available.

The short answer

A promising study result means a drug worked better than a comparator under controlled trial conditions. It does not mean the drug is approved, available, or legal to use outside that trial. The gap between a positive research finding and a product a patient can access runs through FDA review of the full clinical package, a possible DEA rescheduling proceeding, manufacturing scale-up, insurance coverage decisions, and the building of a trained provider network. Each of these takes time, some of them fail, and none of them is guaranteed by a good Phase 3 result. People who read about a promising study and assume access will follow shortly are working from an incomplete understanding of how drug development and approval actually work.

What a clinical trial result means

A clinical trial tests a specific hypothesis under defined conditions: this drug, at this dose, given this way, to this population, at these sites, produces this outcome compared to this control. A positive result says the hypothesis held under those conditions. It does not say the drug works for everyone with the condition, that it is safe in broader populations, that the FDA will agree the trial design was adequate, or that the agency will approve the drug for the indication studied. It also does not say the drug will remain positive in a replication study, which the FDA sometimes requires. IND applications and FDA oversight of psychedelic clinical trials covers what the FDA looks for in a trial design.

The FDA approval process is a separate gate

A drug becomes available for commercial use only after the FDA approves a New Drug Application. The NDA requires the full clinical package: all trials, all safety data, the manufacturing process, and the proposed labeling. The FDA review period is typically six to ten months for priority review and ten to twelve months for standard review after a complete submission, and the agency can issue a Complete Response Letter requesting more data rather than approving. The MAPS MDMA NDA, submitted in 2023 on the basis of two positive Phase 3 trials, received a Complete Response Letter in 2024 and a request for an additional Phase 3 study. A positive Phase 3 is necessary but not sufficient. Drug development timelines and what FDA approval actually requires covers the full path.

Rescheduling is an additional step

If the FDA approves a drug that is a Schedule I substance, the DEA must separately reschedule that substance, or the approved drug product, before it can be prescribed and dispensed. The DEA follows its own process, which can take months to years. When the FDA approved Epidiolex, a cannabis-derived drug for epilepsy, the DEA rescheduled the drug in about ninety days, but that was unusually fast for a politically uncomplicated action on a pediatric epilepsy drug. Rescheduling for a psilocybin or MDMA product would occur in a different political environment. An investor or patient who assumes commercial availability follows immediately from FDA approval is missing this step.

Access programs are limited, not a workaround

Some people point to expanded access, compassionate use, or the Right to Try Act as ways to get a not-yet-approved drug. Expanded access is available in specific circumstances for individual patients with serious conditions who have no alternatives, and it requires FDA authorization, the manufacturer’s cooperation, and a physician to sponsor the request. The Right to Try Act has a narrow scope and has not been a practical route to psychedelic access. What is the Right to Try Act and does it apply to psychedelics? covers its limits. These programs do not provide broad access, and they depend on the manufacturer having sufficient supply and willingness to participate.

Manufacturing, supply, and distribution have to be built

A drug that has been studied in clinical trials under controlled conditions may have been produced in small quantities by a contract manufacturer for research purposes. Scaling that process to commercial supply, validating the manufacturing process to FDA standards, and building a distribution network takes time and investment. A drug that does not yet have a commercial manufacturer cannot be approved on a timeline that assumes one is ready.

The provider and reimbursement infrastructure does not exist yet

For a psychedelic-assisted therapy, even an approved drug has to reach patients through providers trained to administer it, in settings equipped for the session, and at a cost someone will pay. The trained-provider network, the certified treatment centers, and the insurance coverage decisions all have to be built after approval. A drug that requires hours of supervised administration in a specialized setting faces a different access problem than a daily pill, and that problem is not solved by FDA approval. Can I use insurance for psychedelic services or treatment? and Clinical trials vs. legal access programs: what’s the difference? cover the access picture.

State-regulated programs are not FDA approval

Oregon and Colorado have licensed psilocybin services, and participants can access those services without a prescription or a diagnosis. Those programs operate under state law, outside the FDA’s drug approval process, and they are not available to everyone in every state. A research result involving psilocybin does not make psilocybin services more available in Oregon or Colorado, and it does not make them available in states without a program. Psychedelic Law 101: what is actually legal in the US? covers what is currently accessible and where.

The typical timeline from first trial to patient access

From first-in-human trials to FDA approval, the median development timeline across all drug types is over a decade, with a success rate from Phase 1 to approval of roughly ten percent. Psychedelic programs that began Phase 2 studies in the 2010s and reached Phase 3 in the early 2020s have moved faster than average for the field, and the COMPASS COMP360 program is plausible for approval in the late 2020s on its current trajectory. That timeline is unusually fast for drug development. Even for programs that succeed, the gap from a published positive study to a patient receiving a prescription is measured in years, not months.

When public information may be enough

The FDA’s drug approval process, the NDA review timeline, and the DEA scheduling process are well documented, and the agency’s public statements about psychedelic trials are available. A person who wants to understand why a drug they read about is not available can read those sources and learn the answer. What FDA approval does and does not mean for psychedelic treatments covers the approval question directly.

When you should speak with a lawyer

A patient seeking access to a not-yet-approved treatment may have options through expanded access or a clinical trial, and a lawyer or a physician familiar with FDA access pathways can help identify them. An investor assessing a company whose thesis depends on near-term approval should have regulatory counsel review the development status and the FDA’s public correspondence before pricing the risk.

You might also want to read

This article provides general legal information, not legal advice, and does not create an attorney-client relationship. Psychedelic law differs by state and changes over time. Consult a licensed attorney in your jurisdiction before acting on anything described here.